Evidence map›Paper›PMID 31682087›Full record

ArticleAnnals of clinical and translational neurology2019

Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis.

Christian W Keller, Tobias Ruck, Donal McHugh, Steffen Pfeuffer, Catharina C Gross, Catharina Korsukewitz, Nico Melzer, Luisa Klotz, Sven G Meuth, Christian Münz and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of clinical and translational neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020
    Review
  6. Detecting and predicting neutralization of alemtuzumab responses in MS.Neurology(R) neuroimmunology & neuroinflammation · 2020
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Christian W KellerDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.ORCID 0000-0003-2276-0003
Tobias RuckDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Donal McHughLaboratory of Viral Immunobiology, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-3791-0038
Steffen PfeufferDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Catharina C GrossDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Catharina KorsukewitzDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Nico MelzerDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Luisa KlotzDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Sven G MeuthDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Christian MünzLaboratory of Viral Immunobiology, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-6419-1940
Falk NimmerjahnDepartment of Biology, Institute of Genetics, University of Erlangen-Nürnberg, Erlangen, Germany.
Heinz WiendlDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Jan D LünemannDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.ORCID 0000-0002-3007-708X
University Hospital Münster · DEUniversity of Zurich · CHFriedrich-Alexander-Universität Erlangen-Nürnberg · DE

Funding

Genzyme Therapeutics Ltd.German Ministry of Education, Science, Research and Technology 01GI1603DGerman Ministry of Education, Science, Research and Technology FKZ01FI1603AHartmann Müller FoundationNovartis Foundation for Medical-Biological ResearchOlga Mayenfisch FoundationSassella FoundationSwiss Multiple Sclerosis SocietySwiss National Foundation 31003A-169664
6 · The paper itself

Abstract

Allelic variants of genes encoding for the Fc gamma receptors IIIA and IIA have been associated with the clinical response to cell-depleting antibodies in lymphoma patients. Here, we tested the hypothesis that FCGR3A and FCGR2A high-affinity polymorphisms predict clinical outcomes to alemtuzumab therapy in 85 patients with relapsing-remitting multiple sclerosis. No differences in clinical and MRI-based efficacy parameters, the development of severe infusion-associated reactions and secondary autoimmune diseases during a 2 year follow-up was observed based on FCGR3A or FCGR2A polymorphisms. This study does not support the use of FCGR genetic variants to predict clinical outcomes to alemtuzumab.

Indexed as

Outcome Assessment, Health CareAdolescentAdultAlemtuzumabFemaleFollow-Up StudiesHumansImmunologic FactorsMaleMiddle AgedMultiple Sclerosis, Relapsing-RemittingReceptors, IgGYoung AdultAlemtuzumabFCGR2A protein, humanFCGR3A protein, humanImmunologic FactorsReceptors, IgG

Identifiers

PMID31682087
PMCPMC6917309
OpenAlexW2983158244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.